Solventum (NYSE:SOLV) Stock Keeps “Overweight” Rating at Piper Sandler

Solventum (NYSE:SOLV)‘s stock had its “overweight” rating reissued by analysts at Piper Sandler in a note issued to investors on Friday, Benzinga reports. They currently have a $110.00 target price on the stock, up from their prior target price of $105.00. Piper Sandler‘s price objective points to a potential upside of 20.10% from the company’s current price.

SOLV has been the topic of several other reports. Weiss Ratings raised shares of Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Mizuho set a $113.00 target price on Solventum in a research report on Thursday, August 6th. Canadian Imperial Bank of Commerce set a $35.00 price objective on Solventum in a report on Wednesday, October 28th. Wedbush boosted their price objective on Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Solventum in a research note on Friday. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Solventum presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.00.

Solventum Price Performance

NYSE:SOLV opened at $91.59 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74. The firm has a market cap of $15.59 billion, a price-to-earnings ratio of 11.15, a price-to-earnings-growth ratio of 1.30 and a beta of 0.69. The company has a 50 day moving average price of $87.75 and a 200-day moving average price of $78.64. Solventum has a 1-year low of $62.38 and a 1-year high of $94.16.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, November 5th. The company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.11. The firm had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.93 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The business’s revenue was down 7.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.50 EPS. Equities research analysts forecast that Solventum will post 7.21 EPS for the current year.

Institutional Investors Weigh In On Solventum

Several institutional investors have recently bought and sold shares of SOLV. WINTON GROUP Ltd acquired a new position in Solventum in the 2nd quarter valued at about $3,402,000. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in shares of Solventum in the 2nd quarter valued at approximately $150,066,000. Squarepoint Ops LLC grew its stake in shares of Solventum by 6,103.8% in the 2nd quarter. Squarepoint Ops LLC now owns 243,128 shares of the company’s stock valued at $18,757,000 after buying an additional 239,209 shares during the period. Lone Peak Global Investors LLC increased its holdings in shares of Solventum by 38.5% during the 2nd quarter. Lone Peak Global Investors LLC now owns 433,128 shares of the company’s stock worth $33,416,000 after buying an additional 120,352 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Solventum during the 2nd quarter worth approximately $1,018,000.

More Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Adjusted Q3 EPS of $1.45 topped the $1.34 analyst consensus, while revenue of $1.95 billion slightly exceeded expectations. Solventum Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Solventum raised its 2026 adjusted EPS outlook to $7.20–$7.30 and expects organic sales growth toward the high end of its 2.5%–3.0% range, signaling confidence in its full-year performance. Solventum signals 2026 EPS of $7.20 to $7.30 as separation passes 90% completion
• Neutral Sentiment: Management attributed much of the quarterly organic-sales decline to customers ordering ahead of an ERP system cutover, which created a tough comparison; the company said the 3M separation is more than 90% complete. Solventum beats Q3 expectations as 3M separation nears completion
• Negative Sentiment: Reported sales fell 7% year over year and organic sales declined 2.8%. Although the company cited order timing related to the ERP transition, the declines may keep investors cautious about underlying demand. Solventum Reports Third Quarter 2026 Financial Results

Solventum Company Profile

Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.